Equity Profile

GRFS

Grifols, S.A.

Health CareBiotechnology$4.9B

Feb28Mon

Pre-Earnings Brief

UpcomingQ3-2021After Close9:00 AM EST

Company Snapshot

Grifols, S.A. is a global healthcare company specializing in the production of plasma-derived medicines and other biopharmaceuticals....

Key Metrics to Watch

Revenue Growth

Revenue growth is vital as it indicates the company's ability to expand its market presence and meet demand for its products.

N/A

Earnings Per Share (EPS)

EPS is a key measure of profitability and is closely watched by investors to gauge the company's financial health.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

GRFS Q3-2021 Earnings Preview

Context

Company Snapshot

Grifols, S.A. is a global healthcare company specializing in the production of plasma-derived medicines and other biopharmaceuticals. Operating in the biotechnology sector, Grifols plays a crucial role in treating various medical conditions, making it significant in the health care industry.

Earnings Scorecard·Last 7Q

EPS Beat Streak

EPS Beat Rate

14%

Avg EPS Surprise

-3.86%

Avg Stock Reaction

+1.41%

Last Quarter Recap

In the last quarter, Grifols reported an EPS of $0.24, which was below the expected $0.27, resulting in a negative surprise of 12.26%. Despite this, the stock saw a slight increase of 1.76% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are cautious heading into the earnings report, given the recent EPS miss and lack of guidance from management. Investors will be looking for signs of recovery and growth.

Bull Case

If Grifols can demonstrate strong revenue growth and improved plasma collection volumes, it may signal a turnaround, boosting investor confidence.

Bear Case

Conversely, if the company fails to show significant improvement in key metrics, it could lead to further declines in stock performance.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current plasma collection volume and how does it compare to previous quarters?

This metric is crucial as it directly affects Grifols' ability to produce its medicines and meet market demand.

What are the company's expectations for revenue growth in the upcoming quarters?

Understanding revenue projections will help investors gauge the company's recovery trajectory and overall health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for recovery in plasma collection volumes, which could rebound more strongly than anticipated.

Supporting Evidence

The options market is pricing a larger move than historical averages, suggesting that investors expect volatility.

Grifols has a history of surprising on revenue growth when plasma collection improves, which may not be fully reflected in current estimates.

Key Risk

If plasma collection volume exceeds expectations, it could lead to a significant upward revision in revenue forecasts.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is focused on Grifols' ability to recover from recent setbacks and demonstrate growth in key operational metrics.

Bull Confirmed If

A significant increase in plasma collection volume, exceeding previous quarter levels, would confirm the bull case.

Bear Confirmed If

If plasma collection volume declines or revenue growth is stagnant, it would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±6.05%

Historical Avg

±1.5%

Pricing rich

The options market is pricing in a significant move of about 6.05%, indicating heightened uncertainty around the earnings report.

Options are pricing ±6.1% while GRFS has averaged ±1.5% over the last 7 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

35.6%

Calls (22K)P/C Ratio: 0.33Puts (600)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Grifols beats expectations, history suggests the stock could rise by an average of 0.10%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but cautious commentary is provided, the stock may experience muted movement.

Miss

A miss on key metrics could lead to a decline, with history suggesting an average drop of 1.35%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on plasma collection volume and any changes in collection strategy.
2Management's outlook on revenue growth for the next quarter.
3Any new product developments or market expansions.
4Insights into cost management and operational efficiency improvements.
5Responses to competitive pressures in the biotechnology space.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Feb25

DHILReported

Diamond Hill Investment Group, Inc.

RecapView

Feb28

JLLReported

Company Snapshot

Grifols, S.A. is a global healthcare company specializing in the production of plasma-derived medicines and other biopharmaceuticals....

Key Metrics to Watch

Revenue Growth

Revenue growth is vital as it indicates the company's ability to expand its market presence and meet demand for its products.

N/A

Earnings Per Share (EPS)

EPS is a key measure of profitability and is closely watched by investors to gauge the company's financial health.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

GRFS Q3-2021 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 7Q

EPS Beat Streak

EPS Beat Rate

14%

Avg EPS Surprise

-3.86%

Avg Stock Reaction

+1.41%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are cautious heading into the earnings report, given the recent EPS miss and lack of guidance from management. Investors will be looking for signs of recovery and growth.

Bull Case

If Grifols can demonstrate strong revenue growth and improved plasma collection volumes, it may signal a turnaround, boosting investor confidence.

Bear Case

Conversely, if the company fails to show significant improvement in key metrics, it could lead to further declines in stock performance.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current plasma collection volume and how does it compare to previous quarters?

This metric is crucial as it directly affects Grifols' ability to produce its medicines and meet market demand.

What are the company's expectations for revenue growth in the upcoming quarters?

Understanding revenue projections will help investors gauge the company's recovery trajectory and overall health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for recovery in plasma collection volumes, which could rebound more strongly than anticipated.

Supporting Evidence

The options market is pricing a larger move than historical averages, suggesting that investors expect volatility.

Grifols has a history of surprising on revenue growth when plasma collection improves, which may not be fully reflected in current estimates.

Key Risk

If plasma collection volume exceeds expectations, it could lead to a significant upward revision in revenue forecasts.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is focused on Grifols' ability to recover from recent setbacks and demonstrate growth in key operational metrics.

Bull Confirmed If

A significant increase in plasma collection volume, exceeding previous quarter levels, would confirm the bull case.

Bear Confirmed If

If plasma collection volume declines or revenue growth is stagnant, it would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±6.05%

Historical Avg

±1.5%

Pricing rich

The options market is pricing in a significant move of about 6.05%, indicating heightened uncertainty around the earnings report.

Options are pricing ±6.1% while GRFS has averaged ±1.5% over the last 7 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

35.6%

Calls (22K)P/C Ratio: 0.33Puts (600)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Grifols beats expectations, history suggests the stock could rise by an average of 0.10%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but cautious commentary is provided, the stock may experience muted movement.

Miss

A miss on key metrics could lead to a decline, with history suggesting an average drop of 1.35%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on plasma collection volume and any changes in collection strategy.
2Management's outlook on revenue growth for the next quarter.
3Any new product developments or market expansions.
4Insights into cost management and operational efficiency improvements.
5Responses to competitive pressures in the biotechnology space.